Drug for Alzheimer’s shows promise in reducing symptoms: Eisai
In a research experiment, a treatment for Alzheimer’s disease developed by US company Biogen Inc. and Japanese pharmaceutical company Eisai Co. showed promise for reducing the severity of symptoms.
Lecanemab is a medication Eisai hopes to have approved by the government in 2023.
According to Eisai, the medication slowed the progression of symptoms like deteriorating memory and impaired judgment by 27% in the clinical trial compared to a placebo.
A total of 1,800 patients with early symptoms from Japan, the US, Europe, and China participated in the trial.
The announcement follows the rejection of aducanumab, a different Alzheimer’s disease treatment co-developed by Eisai and Biogen, by a panel at Japan’s health ministry in December last year.
According to Eisai, lecanemab eliminates a particular class of protein called amyloid beta, which builds up inside the brain and kills nerve cells.
Save/Share this story with QR CODE
Disclaimer
This article is for informational purposes only and does not constitute endorsement of any specific technologies or methodologies and financial advice or endorsement of any specific products or services.
π© Need to get in touch?
Feel free to Email Us for comments, suggestions, reviews, or anything else.
We appreciate your reading. πSimple Ways To Say Thanks & Support Us:
1.) β€οΈGIVE A TIP. Send a small donation thru Paypalπβ€οΈ
Your DONATION will be used to fund and maintain NEXTGENDAY.com
Subscribers in the Philippines can make donations to mobile number 0917 906 3081, thru GCash.
3.) π BUY or SIGN UP to our AFFILIATE PARTNERS.
4.) π Give this news article a THUMBS UP, and Leave a Comment (at Least Five Words).
AFFILIATE PARTNERS
World Class Nutritional Supplements - Buy Highest Quality Products, Purest Most Healthy Ingredients, Direct to your Door! Up to 90% OFF.
Join LiveGood Today - A company created to satisfy the world's most demanding leaders and entrepreneurs, with the best compensation plan today.